Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Inovalon stock

Own Inovalon stock in just a few minutes.

Inovalon Holdings, Inc is a health information services business based in the US. Inovalon shares (INOV) are listed on the NASDAQ and all prices are listed in US Dollars. Inovalon employs 1,836 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Inovalon

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INOV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Inovalon share price

Use our graph to track the performance of INOV stocks over time.

Inovalon shares at a glance

Information last updated 2021-04-29.
52-week range$15.15 - $30.77
50-day moving average $28.64
200-day moving average $24.12
Wall St. target price$29.38
PE ratio 200.3425
Dividend yield N/A (0%)
Earnings per share (TTM) $0.15

Buy Inovalon shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Inovalon stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Inovalon under- or over-valued?

Valuing Inovalon stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Inovalon's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Inovalon's P/E ratio

Inovalon's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 200x. In other words, Inovalon shares trade at around 200x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Inovalon's PEG ratio

Inovalon's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Inovalon's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Inovalon's EBITDA

Inovalon's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $189.7 million.

The EBITDA is a measure of a Inovalon's overall financial performance and is widely used to measure a its profitability.

Inovalon financials

Revenue TTM $667.5 million
Operating margin TTM 11.2%
Gross profit TTM $499.7 million
Return on assets TTM 2.41%
Return on equity TTM 3.23%
Profit margin 3.38%
Book value $4.56
Market capitalisation $4.6 billion

TTM: trailing 12 months

Shorting Inovalon shares

There are currently 3.6 million Inovalon shares held short by investors – that's known as Inovalon's "short interest". This figure is 1.1% down from 3.6 million last month.

There are a few different ways that this level of interest in shorting Inovalon shares can be evaluated.

Inovalon's "short interest ratio" (SIR)

Inovalon's "short interest ratio" (SIR) is the quantity of Inovalon shares currently shorted divided by the average quantity of Inovalon shares traded daily (recently around 467191.59001314). Inovalon's SIR currently stands at 7.61. In other words for every 100,000 Inovalon shares traded daily on the market, roughly 7610 shares are currently held short.

However Inovalon's short interest can also be evaluated against the total number of Inovalon shares, or, against the total number of tradable Inovalon shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovalon's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Inovalon shares in existence, roughly 20 shares are currently held short) or 0.0476% of the tradable shares (for every 100,000 tradable Inovalon shares, roughly 48 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Inovalon.

Find out more about how you can short Inovalon stock.

Inovalon share dividends

We're not expecting Inovalon to pay a dividend over the next 12 months.

Inovalon share price volatility

Over the last 12 months, Inovalon's shares have ranged in value from as little as $15.15 up to $30.77. A popular way to gauge a stock's volatility is its "beta".

INOV.US volatility(beta: 0.6)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovalon's is 0.5962. This would suggest that Inovalon's shares are less volatile than average (for this exchange).

Inovalon overview

Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare. It operates Inovalon ONE Platform, an integrated, real-time cloud native platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities. In addition, it offers advisory, implementation, and support services. The company serves health plans and provider organizations, as well as pharmaceutical, medical device, and diagnostics companies. Its platforms include information of data pertaining to approximately one million physicians; 574,000 clinical facilities; and approximately 332 million individuals and 61 billion medical events.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site